novo nordisk glp-1 news In the original clinical trials looking at semaglutide (the in Nordisk's Ozempic and Wegovy) and tirzepatide (in Eli Lilly's Mounjaro and Zepbound), patients gained back most of the weight after Trump low-cost GLP-1 plan a

The semaglutide shortage has officially ended in the USwhich means the GLP-1 drug industry is about to undergo massive changes.

This comprehensive review synthesizes current evidence on the mechanisms, established ...

Optum Rx is launching a new weight management program aimed at improving outcomes and addressing affordability

If you want to enhance your health and reach your weight loss goals, knowing about GLP-1 agonists can be key

However, its future trajectory is far from linear as many uncertainties remain, e.g., acceptance of obesity as a chronic disease, budget impact faced by payers and health systems willingness and ability to pay, the readout of further cardiovascular outcomes trials after the high profile results of 2023s SELECT trial for Wegovy, or new entrants challenging first generation therapies with alternative mechanisms of action (MoA) to address shortcomings such as gastrointestinal tolerability, current drugs being injectables, or the durability and quality of weight loss which distinguishes between fat and lean body mass

Gastrointestinal symptoms such as nausea, constipation, and indigestion are most common and usually subside as your body adjusts